The meta-analysis of randomized clinical trials, the German and Spanish registries, and a re-analysis of BSR Biologics Register (BSRBR) data suggest that TNF inhibitor use is associated with an approximate doubling of risk of serious infection, particularly early on in the course of therapy.12, -14 The RAPID study showed 7% serious infections. Here, TNF is linked to infection.